Biotech Values

[nsomniyak]

I am long ITMN for the short term (no longer than next Friday, as I will probably exit by writing covered calls) with my investment thesis being that the non-dilutive cash infusion from the Roche deal will force short covering.

After that, for the medium and long term, yes, I definitely would see ITMN as a short candidate. They will fund the next leg of their research, but it is a bet the farm deal on European approval, which won't come until next year. Also - the chart is almost a comical head and shoulders - looks like a side view of a ten gallon hat :)